HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

National Prevalence of Multidrug-Resistant Organisms

Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, discusses his research on the national prevalence of multidrug-resistant organisms.

Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, discusses his research on the national prevalence of multidrug-resistant organisms.

Interview Transcript (slightly modified for readability)

“We studied several organisms; we studied multidrug-resistant Enterobacteriaceae, multidrug-resistant Acinetobacter, multidrug-resistant Pseudomonas, [and] ESBL, or extended-spectrum β-lactamase-producing organisms as well. We studied these because, as many of you are familiar with the 2013 CDC Antibiotic Threat Report, these organisms were categorized as urgent or serious threats, and it’s one of the reasons why we really selected these organisms, to get an idea of how much is really out there in the overall healthcare setting.”